STOCK TITAN

Certara, Inc. - CERT STOCK NEWS

Welcome to our dedicated page for Certara news (Ticker: CERT), a resource for investors and traders seeking the latest updates and insights on Certara stock.

Certara, Inc. (NASDAQ: CERT) delivers biosimulation solutions and model-informed drug development services that accelerate pharmaceutical innovation. This page provides comprehensive coverage of Certara's latest news, including regulatory milestones, strategic partnerships, and advancements in simulation technology.

Investors and industry professionals will find timely updates on earnings reports, product launches, and scientific developments shaping the drug development landscape. Our curated collection features press releases on regulatory submissions, technology platform enhancements, and collaborations with biopharma leaders.

Key focus areas include Certara's biosimulation software updates, regulatory science achievements, and innovations in quantitative pharmacology. Bookmark this page to stay informed about developments impacting clinical trial optimization and global drug approval processes.

Rhea-AI Summary
Certara, Inc. (CERT) introduces Simcyp™ Biopharmaceutics software, aiding drug developers in formulating complex novel and generic small molecule medicines quickly and cost-effectively. The software replaces costly clinical bioequivalence studies, optimizes formulations for complex drugs, and delivers value across critical areas to achieve formulation success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.74%
Tags
none
-
Rhea-AI Summary
CERT - Certara, Inc. (Nasdaq: CERT) reports 1% revenue growth in Q3 2023, with $85.6 million revenue and $49.0 million net loss. The company reiterates full year 2023 financial guidance with revenue expected in the range of $345 million to $360 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
-
Rhea-AI Summary
Certara, Inc. to release Q3 2023 financial results and participate in Stephens Annual Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.87%
Tags
conferences earnings
Rhea-AI Summary
Certara, Inc. successfully supports 300 completed submissions to regulatory agencies worldwide
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
none
-
Rhea-AI Summary
Certara, Inc. to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
conferences
-
Rhea-AI Summary
Certara's Simcyp group has been awarded two new grants from the FDA to expand its predictive models for drug virtual bioequivalence (VBE) and create a formulation toolbox for topically applied drugs. These capabilities will enable safer, faster, and more cost-effective product development. Virtual bioequivalence (VBE) trial simulations using PBPK modeling can reduce or replace costly and time-consuming clinical trials. The grants will also support the development of a reliable dermal PBPK model for lower risk and more efficient development of generic drug products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.14%
Tags
none
Rhea-AI Summary
Certara, a global leader in biosimulation, reported its financial results for the second quarter of fiscal year 2023. Revenue was $90.5 million, net income was $4.7 million, and adjusted EBITDA was $32.4 million. The company's software business performed well, but lower growth in services due to cautious spending led to a restatement of the 2023 outlook. Certara is updating its full year 2023 guidance with revenue expected in the range of $345 million to $360 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.65%
Tags
-
Rhea-AI Summary
Certara, a global leader in Biosimulation, announced that Korea Institute of Toxicology (KIT) will implement Certara’s Pinnacle 21 Enterprise and SEND Explorer software. The software optimizes data analysis and visualization for regulatory compliance and enables scientists to gain scientific insight. Pinnacle 21 Enterprise validates compliance with CDISC standards and has been adopted by FDA and PMDA. SEND Explorer provides advanced viewing and visualization capabilities for nonclinical study data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
conferences
Certara, Inc.

Nasdaq:CERT

CERT Rankings

CERT Stock Data

2.28B
121.01M
2.27%
96.57%
3.34%
Health Information Services
Services-prepackaged Software
Link
United States
RADNOR